r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid has been researched along with Cardiomyopathies in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al Azzam, W; Antoni, G; Bergström, M; Biswas, S; Chen, C; Cheriyan, J; Cleveland, M; Cookson, L; Falk, RH; Galette, P; Janiczek, RL; Kwong, RY; Lukas, MA; Millns, H; Richards, D; Schneider, I; Solomon, SD; Sörensen, J; Storey, J; Thompson, D; van Dongen, G; Vugts, DJ; Wall, A; Wechalekar, A; Wikström, G | 1 |
1 trial(s) available for r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid and Cardiomyopathies
| Article | Year |
|---|---|
Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.
Topics: Aged; Aged, 80 and over; Amyloidosis; Antibodies, Monoclonal; Carboxylic Acids; Cardiomyopathies; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Myocardium; Positron-Emission Tomography; Predictive Value of Tests; Pyrrolidines; Serum Amyloid P-Component; Time Factors; Treatment Outcome; United Kingdom; United States; Ventricular Function, Left; Ventricular Remodeling | 2022 |